LifeMD (NASDAQ:LFMD) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

07 May 2026, 00:08 by Amy Steele · The Cerbat Gem

LifeMD (NASDAQ:LFMD – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06), Zacks reports. The firm had revenue of $50.16 million for the quarter, compared to analyst estimates of $48.84 million. LifeMD had a negative return on equity of 83.93% and a net margin of 6.58%.

Here are the key takeaways from LifeMD’s conference call:

Q1 revenue of $50.2 million beat guidance and the company added >42,000 net telehealth subscribers (its largest quarter), ending with >365,000 subscribers; management reaffirmed 2026 guidance of $220–$230M and a path to >$250M revenue and >$25M adjusted EBITDA run‑rate by Q4.
Rapid traction in core care areas — weight management sign‑ups rose ~120% sequentially to nearly 100,000 patients with improved CACs, and the women’s health program grew >7x from the Q4 base with on‑therapy retention north of 80%.
Gross margin expanded ~420 bps to 88% driven by in‑house pharmacy and lower fulfillment costs, but Q1 showed a GAAP net loss of $9.6M and an adjusted EBITDA loss of ~$4.5M due to front‑loaded marketing that management expects will normalize and improve profitability in H2.
Scaling levers — aggressive AI deployment to increase provider capacity, a 22,500 sq ft, 50‑state pharmacy processing ~20,000 prescriptions/month, and insurance coverage rolling from ~112M toward ~230M covered lives (including a Medicare GLP‑1 Bridge launching July 1) — are positioned to support retention and margin expansion.
Strategic and execution risks remain as the product mix shifts from compounded to branded GLP‑1s (pressuring YoY revenue and producing variable unit economics), details on Novo/Lilly partnerships are limited under NDA, and Q2 guide is modest at $47–$50M revenue and adjusted EBITDA of -$2M to $1M.

LifeMD Trading Up 2.7%

LifeMD stock traded up $0.14 during mid-day trading on Wednesday, reaching $5.27. The company had a trading volume of 1,446,195 shares, compared to its average volume of 1,258,863. LifeMD has a fifty-two week low of $2.56 and a fifty-two week high of $15.84. The company has a market cap of $250.85 million, a P/E ratio of 20.27 and a beta of 2.03. The business has a fifty day simple moving average of $3.84 and a 200 day simple moving average of $3.94.

Key Stories Impacting LifeMD

Here are the key news stories impacting LifeMD this week:

Positive Sentiment: Q1 revenue beat expectations and margins improved — LifeMD reported revenue of ~$50.2M (above consensus ~ $48.8M) and said gross margin expanded ~420 basis points to 88%, reflecting a better revenue mix and lower fulfillment costs, which supports higher profitability potential. GlobeNewswire: Q1 Results
Positive Sentiment: Analyst sentiment remains constructive — brokerages maintain favorable ratings (consensus “Moderate Buy”; BTIG “Buy”), which can support demand for the stock. Analyst Coverage
Neutral Sentiment: Adjusted EBITDA and investor materials available — the company reported an adjusted EBITDA loss of $4.5M (in line with guidance) and posted the press release and slide deck; investors can review the call and slides for detail on margin drivers and customer metrics. Q1 Slide Deck
Negative Sentiment: EPS missed consensus — LifeMD reported a GAAP loss of $0.20/sh versus a consensus loss of $0.14, which is a near-term earnings disappointment and may pressure sentiment. Zacks: Q1 Loss
Negative Sentiment: Q2 revenue guide well below Street — the company issued Q2 revenue guidance of $47.0M–$50.0M versus consensus ~ $53.5M, signaling near-term top-line pressure and raising downside risk to estimates. (Company guidance release)
Negative Sentiment: FY revenue guide is mixed and EPS guidance absent — FY2026 revenue was guided to $220M–$230M (broadly in line with Street), but the company did not provide EPS guidance, which leaves earnings visibility limited for investors. (Company guidance release)
Negative Sentiment: Weak profitability ratios remain a concern — commentary and filings show a very negative return on equity (~-83.9%) despite a reported net margin figure, highlighting past losses and capital structure/earnings volatility. MarketBeat: Metrics

Hedge Funds Weigh In On LifeMD

A number of hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of LifeMD by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock worth $270,000 after purchasing an additional 2,235 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after purchasing an additional 2,452 shares during the period. Invesco Ltd. lifted its holdings in shares of LifeMD by 18.8% during the fourth quarter. Invesco Ltd. now owns 24,464 shares of the company’s stock worth $83,000 after purchasing an additional 3,870 shares during the period. Rhumbline Advisers lifted its holdings in shares of LifeMD by 8.7% during the second quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock worth $730,000 after purchasing an additional 4,281 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of LifeMD by 187.4% during the second quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock worth $138,000 after purchasing an additional 6,614 shares during the period. Institutional investors and hedge funds own 35.52% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on LFMD. Cantor Fitzgerald restated an “overweight” rating on shares of LifeMD in a research report on Tuesday, March 10th. HC Wainwright raised their target price on shares of LifeMD from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. BTIG Research restated a “buy” rating and issued a $10.00 target price on shares of LifeMD in a research report on Monday. Weiss Ratings restated a “sell (e+)” rating on shares of LifeMD in a research report on Friday, March 27th. Finally, Mizuho upgraded shares of LifeMD from a “neutral” rating to an “outperform” rating and raised their target price for the company from $6.00 to $8.00 in a research report on Monday, March 16th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, LifeMD has an average rating of “Moderate Buy” and an average price target of $9.14.

Read Our Latest Stock Analysis on LifeMD

LifeMD Company Profile

(Get Free Report)

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.